Integrated multi-omics analyses of COVID-19-associated Rapid pulmonary fibrosis (RPF) patients and murine models reveal that CD163+ macrophages drive rapid pulmonary fibrosis progression via SPP1 secretion, identifying the CD163+-SPP1 axis as a potential therapeutic target (56). Here, CD163 is linked to pulmonary fibrosis.